10月30日周四盘前，西维斯健康（CVS）股价大跌5.09%，引发市场广泛关注。
消息面上，多家华尔街投行对西维斯健康的目标价进行了调整。其中，杰富瑞将目标价从92美元上调至98美元，加拿大皇家银行将目标价从81美元上调至93美元。德意志银行更是将目标价从76美元大幅上调至88美元。尽管多数分析师上调了目标价，但市场似乎对公司前景持谨慎态度。
分析人士指出，尽管分析师普遍看好西维斯健康的长期发展，但投资者可能担心短期内公司面临的挑战，如医疗保健行业的激烈竞争和潜在的监管压力。此外，近期整体市场情绪低迷也可能是导致股价下跌的因素之一。投资者将密切关注公司未来的财报表现和业务发展情况。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.